(NASDAQ: PASG) Passage Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Passage Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast PASG's revenue for 2025 to be $617,146,636, with the lowest PASG revenue forecast at $617,146,636, and the highest PASG revenue forecast at $617,146,636. On average, 1 Wall Street analysts forecast PASG's revenue for 2026 to be $1,901,478,823, with the lowest PASG revenue forecast at $1,901,478,823, and the highest PASG revenue forecast at $1,901,478,823.
In 2027, PASG is forecast to generate $327,476,908 in revenue, with the lowest revenue forecast at $327,476,908 and the highest revenue forecast at $327,476,908.